World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Miia Kivipelto; Francesca Mangialasche; Heather M. Snyder; Ricardo Allegri; Sandrine Andrieu; Hidenori Arai; Laura Baker; Sylvie Belleville; Henry Brodaty; Sonia M. Brucki; Ismael Calandri; Paulo Caramelli; Christopher Chen; Howard Chertkow; Effie Chew; Seong H. Choi; Neerja Chowdhary; Lucía Crivelli; Rafael De La Torre; Yifeng Du; Tarun Dua; Mark Espeland; Howard H. Feldman; Maris Hartmanis; Tobias Hartmann; Megan Heffernan; Christiani J. Henry; Chang H. Hong; Krister Håkansson; Takeshi Iwatsubo; Jee H. Jeong; Gustavo Jimenez-Maggiora; Edward H. Koo; Lenore J. Launer; Jenni Lehtisalo; Francisco Lopera; Pablo Martínez-Lage; Ralph Martins; Lefkos Middleton; José L. Molinuevo; Manuel Montero-Odasso; So Y. Moon; Kristal Morales-Pérez; Ricardo Nitrini; Haakon B. Nygaard; Yoo K. Park; Markku Peltonen; Chengxuan Qiu; Yakeel T. Quiroz; Rema Raman; Naren Rao; Vijayalakshmi Ravindranath; Anna Rosenberg; Takashi Sakurai; Rosa M. Salinas; Philip Scheltens; Gustavo Sevlever; Hilkka Soininen; Ana L. Sosa; Claudia K. Suemoto; Mikel Tainta-Cuezva; Lina Velilla; Yongxiang Wang; Rachel Whitmer; Xin Xu; Lisa J. Bain; Alina Solomon; Tiia Ngandu; Maria C. Carrillo

doi:10.1002/alz.12123

World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Miia Kivipelto, Francesca Mangialasche, Heather M. Snyder, Ricardo Allegri, Sandrine Andrieu, Hidenori Arai, Laura Baker, Sylvie Belleville, Henry Brodaty, Sonia M. Brucki, Ismael Calandri, Paulo Caramelli, Christopher Chen, Howard Chertkow, Effie Chew, Seong H. Choi, Neerja Chowdhary, Lucía Crivelli, Rafael De La Torre, Yifeng DuTarun Dua, Mark Espeland, Howard H. Feldman, Maris Hartmanis, Tobias Hartmann, Megan Heffernan, Christiani J. Henry, Chang H. Hong, Krister Håkansson, Takeshi Iwatsubo, Jee H. Jeong, Gustavo Jimenez-Maggiora, Edward H. Koo, Lenore J. Launer, Jenni Lehtisalo, Francisco Lopera, Pablo Martínez-Lage, Ralph Martins, Lefkos Middleton, José L. Molinuevo, Manuel Montero-Odasso, So Y. Moon, Kristal Morales-Pérez, Ricardo Nitrini, Haakon B. Nygaard, Yoo K. Park, Markku Peltonen, Chengxuan Qiu, Yakeel T. Quiroz, Rema Raman, Naren Rao, Vijayalakshmi Ravindranath, Anna Rosenberg, Takashi Sakurai, Rosa M. Salinas, Philip Scheltens, Gustavo Sevlever, Hilkka Soininen, Ana L. Sosa, Claudia K. Suemoto, Mikel Tainta-Cuezva, Lina Velilla, Yongxiang Wang, Rachel Whitmer, Xin Xu, Lisa J. Bain, Alina Solomon, Tiia Ngandu, Maria C. Carrillo

Department of Neurology

Research output: Contribution to journal › Article › peer-review

214 Scopus citations

Abstract

Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer's disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline—from at-risk asymptomatic states to early symptomatic stages—in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.

Original language	English
Pages (from-to)	1078-1094
Number of pages	17
Journal	Alzheimer's and Dementia
Volume	16
Issue number	7
DOIs	https://doi.org/10.1002/alz.12123
State	Published - 1 Jul 2020

Bibliographical note

Funding Information:
Another study in Spain, the “Prevention of cognitive decline after a multimodal intervention combined with epigallocatechin gallate in carriers with subjective cognitive decline” (PENSA study: in Catalan PENSA means “think about”; ClinicalTrials.gov: NCT03978052) is an ongoing project in Barcelona, performed in collaboration with the Hospital del Mar Medical Research Institute (IMIM) and the BarcelonaBeta Brain Research Center (BBRC). PENSA will randomize 200 individuals meeting criteria of subjective cognitive decline (SCD), fulfilling four SCD plus features, including subjects older than 60 years and carriers. The project combines a multidomain lifestyle intervention including diet, physical activity, and cognitive stimulation and training and the administration as dietary supplement of the flavanol from green tea, epigallocatechin gallate (EGCG, 5 to 6 mg/kg up to 532 mg/day). The intervention will last 12 months. Participants will be randomized into one of four study arms (Table 1 ), and the primary outcome is global cognition measured with the ADCS Preclinical Alzheimer Cognitive Composite‐Plus‐exe. Secondary and exploratory outcomes include neuroimaging (structural and functional MRI); microbiota; neuroinflammation biomarkers; metabolomics; blood, brain‐derived exosomes, and CSF neuropathological biomarkers; physical activity, dietary assessments, cognitive training performance, and quality‐of‐life records. The project is primarily funded by the Alzheimer's Association, with additional support from the Spanish Ministry of Science, Innovation and Universities (Instituto Carlos III). APOE4 APOE 4

Funding Information:
This work was supported by the Academy of Finland; Joint Program of Neurodegenerative Disorders—prevention (MIND‐AD) grant through the following funding organizations under the aegis of JPND— www.jpnd.eu: Finland, Suomen Akatemia (Academy of Finland, 291803); Sweden, Vetenskapsrådet (VR) (Swedish Research Council, 529‐2014‐7503) France, French National Agency for Research (ANR), ANR‐14‐JPPS‐0001‐02]; Swedish Research Council grant 2017‐06105; Juho Vainio Foundation, Finnish Medical Foundation; Finnish Social Insurance Institution; Ministry of Education and Culture Research Grant; Finnish Cultural Foundation; Knut and Alice Wallenberg Foundation Sweden; Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden; Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; af Jochnick Foundation Sweden; Alzheimer's Research and Prevention Foundation; the European Research Council Starting Grant (ERC‐804371), Alzheimerfonden Sweden; Region Stockholm (ALF and NSV grants), Sweden. U.S. POINTER trial is supported by the Alzheimer's Association POINTER‐19‐611541 and POINTER‐19‐612024 (PIs: Laura Baker, Mark Espeland, Miia Kivipelto, Rachel Whitmer, and ALZ PIs: Maria C. Carrillo and Heather M. Snyder), and ancillary Neuroimaging study to U.S. POINTER with National Institutes of Health (NIH) grant number R01AG062689 (PI: S Landau). Additional support was provided by the Wake Forest Alzheimer's Disease Core Center (P30AG049638‐01A1). The MYB trial is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Team Grant (APP1095097). The SINGER study was supported by Centre For Healthy Ageing, National University Health System, Singapore. The J‐MINT study is supported by Japan Agency for Medical Research and Development. The Canadian Thumbs Up Platform Trial is part of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase 2, which is funded by the Canadian Institutes of Health Research (CIHR #201901CNA‐417847‐CAN‐ABPI‐ 32054) and a consortium of partners including the Alzheimer Society of Canada. The work in India is made possible by funding from Centre for Brain Research, Bengaluru, India. The PENSA study is funded by the Alzheimer's Association (18PTC‐R‐592192) and the Instituto Carlos III (PI17/00223). MIND‐CHINA was supported by the National Key R&D Program of China from the Ministry of Science and Technology of China (grant no.: 2017YFC1310100), and additional grants were received from the Shandong Taishan Scholar Program, Shandong, China; the Sino‐Sweden joint research project grants from the National Natural Science Foundation of China (NSFC grant no.: 81861138008) and the Swedish Research Council (grants no.: 2017‐00740 and 2017‐05819); and the Joint China‐Sweden Mobility Programme grants from the National Natural Science Foundation of China NSFC (grant no.: 8191101618) and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT, grant no.: CH2019‐8320). GOIZ ZAINDU project has been partially financed by the Health Department of the Basque Government (File No. 2017111120). Paulo Caramelli holds a senior research fellowship () from CNPq, Brazil. SUPERBRAIN was supported by the grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C0479). bolsa de produtividade em pesquisa

Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association

Keywords

Alzheimer's disease
World-Wide FINGERS
cognitive impairment
dementia
lifestyle
multidomain intervention
prevention
randomized controlled trial

Access to Document

10.1002/alz.12123

Cite this

Kivipelto, M., Mangialasche, F., Snyder, H. M., Allegri, R., Andrieu, S., Arai, H., Baker, L., Belleville, S., Brodaty, H., Brucki, S. M., Calandri, I., Caramelli, P., Chen, C., Chertkow, H., Chew, E., Choi, S. H., Chowdhary, N., Crivelli, L., Torre, R. D. L., ... Carrillo, M. C. (2020). World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 16(7), 1078-1094. https://doi.org/10.1002/alz.12123

@article{70d33fe116674780b96aeb4bac8f5642,

title = "World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia",

abstract = "Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer's disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline—from at-risk asymptomatic states to early symptomatic stages—in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.",

keywords = "Alzheimer's disease, World-Wide FINGERS, cognitive impairment, dementia, lifestyle, multidomain intervention, prevention, randomized controlled trial",

author = "Miia Kivipelto and Francesca Mangialasche and Snyder, {Heather M.} and Ricardo Allegri and Sandrine Andrieu and Hidenori Arai and Laura Baker and Sylvie Belleville and Henry Brodaty and Brucki, {Sonia M.} and Ismael Calandri and Paulo Caramelli and Christopher Chen and Howard Chertkow and Effie Chew and Choi, {Seong H.} and Neerja Chowdhary and Luc{\'i}a Crivelli and Torre, {Rafael De La} and Yifeng Du and Tarun Dua and Mark Espeland and Feldman, {Howard H.} and Maris Hartmanis and Tobias Hartmann and Megan Heffernan and Henry, {Christiani J.} and Hong, {Chang H.} and Krister H{\aa}kansson and Takeshi Iwatsubo and Jeong, {Jee H.} and Gustavo Jimenez-Maggiora and Koo, {Edward H.} and Launer, {Lenore J.} and Jenni Lehtisalo and Francisco Lopera and Pablo Mart{\'i}nez-Lage and Ralph Martins and Lefkos Middleton and Molinuevo, {Jos{\'e} L.} and Manuel Montero-Odasso and Moon, {So Y.} and Kristal Morales-P{\'e}rez and Ricardo Nitrini and Nygaard, {Haakon B.} and Park, {Yoo K.} and Markku Peltonen and Chengxuan Qiu and Quiroz, {Yakeel T.} and Rema Raman and Naren Rao and Vijayalakshmi Ravindranath and Anna Rosenberg and Takashi Sakurai and Salinas, {Rosa M.} and Philip Scheltens and Gustavo Sevlever and Hilkka Soininen and Sosa, {Ana L.} and Suemoto, {Claudia K.} and Mikel Tainta-Cuezva and Lina Velilla and Yongxiang Wang and Rachel Whitmer and Xin Xu and Bain, {Lisa J.} and Alina Solomon and Tiia Ngandu and Carrillo, {Maria C.}",

note = "Funding Information: Another study in Spain, the “Prevention of cognitive decline after a multimodal intervention combined with epigallocatechin gallate in carriers with subjective cognitive decline” (PENSA study: in Catalan PENSA means “think about”; ClinicalTrials.gov: NCT03978052) is an ongoing project in Barcelona, performed in collaboration with the Hospital del Mar Medical Research Institute (IMIM) and the BarcelonaBeta Brain Research Center (BBRC). PENSA will randomize 200 individuals meeting criteria of subjective cognitive decline (SCD), fulfilling four SCD plus features, including subjects older than 60 years and carriers. The project combines a multidomain lifestyle intervention including diet, physical activity, and cognitive stimulation and training and the administration as dietary supplement of the flavanol from green tea, epigallocatechin gallate (EGCG, 5 to 6 mg/kg up to 532 mg/day). The intervention will last 12 months. Participants will be randomized into one of four study arms (Table 1 ), and the primary outcome is global cognition measured with the ADCS Preclinical Alzheimer Cognitive Composite‐Plus‐exe. Secondary and exploratory outcomes include neuroimaging (structural and functional MRI); microbiota; neuroinflammation biomarkers; metabolomics; blood, brain‐derived exosomes, and CSF neuropathological biomarkers; physical activity, dietary assessments, cognitive training performance, and quality‐of‐life records. The project is primarily funded by the Alzheimer's Association, with additional support from the Spanish Ministry of Science, Innovation and Universities (Instituto Carlos III). APOE4 APOE 4 Funding Information: This work was supported by the Academy of Finland; Joint Program of Neurodegenerative Disorders—prevention (MIND‐AD) grant through the following funding organizations under the aegis of JPND— www.jpnd.eu: Finland, Suomen Akatemia (Academy of Finland, 291803); Sweden, Vetenskapsr{\aa}det (VR) (Swedish Research Council, 529‐2014‐7503) France, French National Agency for Research (ANR), ANR‐14‐JPPS‐0001‐02]; Swedish Research Council grant 2017‐06105; Juho Vainio Foundation, Finnish Medical Foundation; Finnish Social Insurance Institution; Ministry of Education and Culture Research Grant; Finnish Cultural Foundation; Knut and Alice Wallenberg Foundation Sweden; Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden; Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; af Jochnick Foundation Sweden; Alzheimer's Research and Prevention Foundation; the European Research Council Starting Grant (ERC‐804371), Alzheimerfonden Sweden; Region Stockholm (ALF and NSV grants), Sweden. U.S. POINTER trial is supported by the Alzheimer's Association POINTER‐19‐611541 and POINTER‐19‐612024 (PIs: Laura Baker, Mark Espeland, Miia Kivipelto, Rachel Whitmer, and ALZ PIs: Maria C. Carrillo and Heather M. Snyder), and ancillary Neuroimaging study to U.S. POINTER with National Institutes of Health (NIH) grant number R01AG062689 (PI: S Landau). Additional support was provided by the Wake Forest Alzheimer's Disease Core Center (P30AG049638‐01A1). The MYB trial is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Team Grant (APP1095097). The SINGER study was supported by Centre For Healthy Ageing, National University Health System, Singapore. The J‐MINT study is supported by Japan Agency for Medical Research and Development. The Canadian Thumbs Up Platform Trial is part of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase 2, which is funded by the Canadian Institutes of Health Research (CIHR #201901CNA‐417847‐CAN‐ABPI‐ 32054) and a consortium of partners including the Alzheimer Society of Canada. The work in India is made possible by funding from Centre for Brain Research, Bengaluru, India. The PENSA study is funded by the Alzheimer's Association (18PTC‐R‐592192) and the Instituto Carlos III (PI17/00223). MIND‐CHINA was supported by the National Key R&D Program of China from the Ministry of Science and Technology of China (grant no.: 2017YFC1310100), and additional grants were received from the Shandong Taishan Scholar Program, Shandong, China; the Sino‐Sweden joint research project grants from the National Natural Science Foundation of China (NSFC grant no.: 81861138008) and the Swedish Research Council (grants no.: 2017‐00740 and 2017‐05819); and the Joint China‐Sweden Mobility Programme grants from the National Natural Science Foundation of China NSFC (grant no.: 8191101618) and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT, grant no.: CH2019‐8320). GOIZ ZAINDU project has been partially financed by the Health Department of the Basque Government (File No. 2017111120). Paulo Caramelli holds a senior research fellowship () from CNPq, Brazil. SUPERBRAIN was supported by the grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C0479). bolsa de produtividade em pesquisa Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association",

year = "2020",

month = jul,

day = "1",

doi = "10.1002/alz.12123",

language = "English",

volume = "16",

pages = "1078--1094",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley & Sons Inc.",

number = "7",

}

Kivipelto, M, Mangialasche, F, Snyder, HM, Allegri, R, Andrieu, S, Arai, H, Baker, L, Belleville, S, Brodaty, H, Brucki, SM, Calandri, I, Caramelli, P, Chen, C, Chertkow, H, Chew, E, Choi, SH, Chowdhary, N, Crivelli, L, Torre, RDL, Du, Y, Dua, T, Espeland, M, Feldman, HH, Hartmanis, M, Hartmann, T, Heffernan, M, Henry, CJ, Hong, CH, Håkansson, K, Iwatsubo, T, Jeong, JH, Jimenez-Maggiora, G, Koo, EH, Launer, LJ, Lehtisalo, J, Lopera, F, Martínez-Lage, P, Martins, R, Middleton, L, Molinuevo, JL, Montero-Odasso, M, Moon, SY, Morales-Pérez, K, Nitrini, R, Nygaard, HB, Park, YK, Peltonen, M, Qiu, C, Quiroz, YT, Raman, R, Rao, N, Ravindranath, V, Rosenberg, A, Sakurai, T, Salinas, RM, Scheltens, P, Sevlever, G, Soininen, H, Sosa, AL, Suemoto, CK, Tainta-Cuezva, M, Velilla, L, Wang, Y, Whitmer, R, Xu, X, Bain, LJ, Solomon, A, Ngandu, T & Carrillo, MC 2020, 'World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia', Alzheimer's and Dementia, vol. 16, no. 7, pp. 1078-1094. https://doi.org/10.1002/alz.12123

TY - JOUR

T1 - World-Wide FINGERS Network

T2 - A global approach to risk reduction and prevention of dementia

AU - Kivipelto, Miia

AU - Mangialasche, Francesca

AU - Snyder, Heather M.

AU - Allegri, Ricardo

AU - Andrieu, Sandrine

AU - Arai, Hidenori

AU - Baker, Laura

AU - Belleville, Sylvie

AU - Brodaty, Henry

AU - Brucki, Sonia M.

AU - Calandri, Ismael

AU - Caramelli, Paulo

AU - Chen, Christopher

AU - Chertkow, Howard

AU - Chew, Effie

AU - Choi, Seong H.

AU - Chowdhary, Neerja

AU - Crivelli, Lucía

AU - Torre, Rafael De La

AU - Du, Yifeng

AU - Dua, Tarun

AU - Espeland, Mark

AU - Feldman, Howard H.

AU - Hartmanis, Maris

AU - Hartmann, Tobias

AU - Heffernan, Megan

AU - Henry, Christiani J.

AU - Hong, Chang H.

AU - Håkansson, Krister

AU - Iwatsubo, Takeshi

AU - Jeong, Jee H.

AU - Jimenez-Maggiora, Gustavo

AU - Koo, Edward H.

AU - Launer, Lenore J.

AU - Lehtisalo, Jenni

AU - Lopera, Francisco

AU - Martínez-Lage, Pablo

AU - Martins, Ralph

AU - Middleton, Lefkos

AU - Molinuevo, José L.

AU - Montero-Odasso, Manuel

AU - Moon, So Y.

AU - Morales-Pérez, Kristal

AU - Nitrini, Ricardo

AU - Nygaard, Haakon B.

AU - Park, Yoo K.

AU - Peltonen, Markku

AU - Qiu, Chengxuan

AU - Quiroz, Yakeel T.

AU - Raman, Rema

AU - Rao, Naren

AU - Ravindranath, Vijayalakshmi

AU - Rosenberg, Anna

AU - Sakurai, Takashi

AU - Salinas, Rosa M.

AU - Scheltens, Philip

AU - Sevlever, Gustavo

AU - Soininen, Hilkka

AU - Sosa, Ana L.

AU - Suemoto, Claudia K.

AU - Tainta-Cuezva, Mikel

AU - Velilla, Lina

AU - Wang, Yongxiang

AU - Whitmer, Rachel

AU - Xu, Xin

AU - Bain, Lisa J.

AU - Solomon, Alina

AU - Ngandu, Tiia

AU - Carrillo, Maria C.

N1 - Funding Information: Another study in Spain, the “Prevention of cognitive decline after a multimodal intervention combined with epigallocatechin gallate in carriers with subjective cognitive decline” (PENSA study: in Catalan PENSA means “think about”; ClinicalTrials.gov: NCT03978052) is an ongoing project in Barcelona, performed in collaboration with the Hospital del Mar Medical Research Institute (IMIM) and the BarcelonaBeta Brain Research Center (BBRC). PENSA will randomize 200 individuals meeting criteria of subjective cognitive decline (SCD), fulfilling four SCD plus features, including subjects older than 60 years and carriers. The project combines a multidomain lifestyle intervention including diet, physical activity, and cognitive stimulation and training and the administration as dietary supplement of the flavanol from green tea, epigallocatechin gallate (EGCG, 5 to 6 mg/kg up to 532 mg/day). The intervention will last 12 months. Participants will be randomized into one of four study arms (Table 1 ), and the primary outcome is global cognition measured with the ADCS Preclinical Alzheimer Cognitive Composite‐Plus‐exe. Secondary and exploratory outcomes include neuroimaging (structural and functional MRI); microbiota; neuroinflammation biomarkers; metabolomics; blood, brain‐derived exosomes, and CSF neuropathological biomarkers; physical activity, dietary assessments, cognitive training performance, and quality‐of‐life records. The project is primarily funded by the Alzheimer's Association, with additional support from the Spanish Ministry of Science, Innovation and Universities (Instituto Carlos III). APOE4 APOE 4 Funding Information: This work was supported by the Academy of Finland; Joint Program of Neurodegenerative Disorders—prevention (MIND‐AD) grant through the following funding organizations under the aegis of JPND— www.jpnd.eu: Finland, Suomen Akatemia (Academy of Finland, 291803); Sweden, Vetenskapsrådet (VR) (Swedish Research Council, 529‐2014‐7503) France, French National Agency for Research (ANR), ANR‐14‐JPPS‐0001‐02]; Swedish Research Council grant 2017‐06105; Juho Vainio Foundation, Finnish Medical Foundation; Finnish Social Insurance Institution; Ministry of Education and Culture Research Grant; Finnish Cultural Foundation; Knut and Alice Wallenberg Foundation Sweden; Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden; Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; af Jochnick Foundation Sweden; Alzheimer's Research and Prevention Foundation; the European Research Council Starting Grant (ERC‐804371), Alzheimerfonden Sweden; Region Stockholm (ALF and NSV grants), Sweden. U.S. POINTER trial is supported by the Alzheimer's Association POINTER‐19‐611541 and POINTER‐19‐612024 (PIs: Laura Baker, Mark Espeland, Miia Kivipelto, Rachel Whitmer, and ALZ PIs: Maria C. Carrillo and Heather M. Snyder), and ancillary Neuroimaging study to U.S. POINTER with National Institutes of Health (NIH) grant number R01AG062689 (PI: S Landau). Additional support was provided by the Wake Forest Alzheimer's Disease Core Center (P30AG049638‐01A1). The MYB trial is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Team Grant (APP1095097). The SINGER study was supported by Centre For Healthy Ageing, National University Health System, Singapore. The J‐MINT study is supported by Japan Agency for Medical Research and Development. The Canadian Thumbs Up Platform Trial is part of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase 2, which is funded by the Canadian Institutes of Health Research (CIHR #201901CNA‐417847‐CAN‐ABPI‐ 32054) and a consortium of partners including the Alzheimer Society of Canada. The work in India is made possible by funding from Centre for Brain Research, Bengaluru, India. The PENSA study is funded by the Alzheimer's Association (18PTC‐R‐592192) and the Instituto Carlos III (PI17/00223). MIND‐CHINA was supported by the National Key R&D Program of China from the Ministry of Science and Technology of China (grant no.: 2017YFC1310100), and additional grants were received from the Shandong Taishan Scholar Program, Shandong, China; the Sino‐Sweden joint research project grants from the National Natural Science Foundation of China (NSFC grant no.: 81861138008) and the Swedish Research Council (grants no.: 2017‐00740 and 2017‐05819); and the Joint China‐Sweden Mobility Programme grants from the National Natural Science Foundation of China NSFC (grant no.: 8191101618) and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT, grant no.: CH2019‐8320). GOIZ ZAINDU project has been partially financed by the Health Department of the Basque Government (File No. 2017111120). Paulo Caramelli holds a senior research fellowship () from CNPq, Brazil. SUPERBRAIN was supported by the grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C0479). bolsa de produtividade em pesquisa Publisher Copyright: © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer's disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline—from at-risk asymptomatic states to early symptomatic stages—in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.

AB - Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer's disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline—from at-risk asymptomatic states to early symptomatic stages—in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.

KW - Alzheimer's disease

KW - World-Wide FINGERS

KW - cognitive impairment

KW - dementia

KW - lifestyle

KW - multidomain intervention

KW - prevention

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85087445765&partnerID=8YFLogxK

U2 - 10.1002/alz.12123

DO - 10.1002/alz.12123

M3 - Article

C2 - 32627328

AN - SCOPUS:85087445765

SN - 1552-5260

VL - 16

SP - 1078

EP - 1094

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 7

ER -

World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this